Skip to content
Search

Latest Stories

Submit Guest Post

Coca-Cola to Buy Coffee Chain Costa from Britain’s Whitbread Plc for £3.9 billion

Britain’s Whitbread Plc has agreed to sell its world’s second largest coffee chain Costa to Coca-Cola Co for an enterprise value of £3.9 billion, said in a statement on Friday (31).

The new deal is expected to pave a new way for Coca-Cola Co to move ahead with the new front, other than its traditional sodas.


Coca-Cola Co is expected to get almost 4000 coffee outlets in the UK and other European countries, according to the deal struck unanimously by the Whitbread board understanding the best interest of the shareholders.

Whitbread had been working to demerge its coffee business chain from its hotel chain. The company purchased Costa in 1995 for £19 million pounds when it was a small business chain with only 39 shops.

“A significant majority of net cash proceeds intended to be returned to shareholders. Whitbread will also reduce financial indebtedness and make a contribution to the pension fund, which will both provide headroom for further expansion of Premier Inn in the UK and Germany,” the company said in a release.

The transaction is expected to complete in the first half of 2019. Whitbread aims to focus on the attractive structural growth opportunities for its leading hotel business, Premier Inn, in the UK and Germany, the company added.

“Costa gives Coca-Cola new capabilities and expertise in coffee, and our system can create opportunities to grow the Costa brand worldwide. Hot beverages is one of the few remaining segments of the total beverage landscape where Coca-Cola does not have a global brand. Costa gives us access to this market through a strong coffee platform. I’d like to welcome the team to Coca-Cola and look forward to working with them,” said James Quincey, Coca-Cola President, and CEO commenting on the deal.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

AstraZeneca

AstraZeneca chief executive Pascal Soriot says the company has the science, pipeline and team to deliver its long-term growth ambitions

Getty Images

AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment

  • AstraZeneca expects its restructuring programme to generate $1.5bn in annualised savings by 2029, with most of the money reinvested in research and development.
  • The plan could incur up to $2bn in one-off restructuring costs, although the company expects its overall workforce to continue growing.
  • Third-quarter revenue rose 7 per cent to $16.21bn, while oncology sales increased 17 per cent to $7.77bn.

AstraZeneca has unveiled plans to generate around $1.5bn in annual savings through a three-year restructuring programme, as chief executive Pascal Soriot shifts the focus back to growth and investment in its drug pipeline.

The British-based pharmaceutical group said its Reshaping for Sustainable Growth programme would redirect resources towards research and development, particularly its pipeline of more than 180 projects and emerging technologies.

Keep ReadingShow less